ADAbhinav Dey

Abhinav Dey

*This is an algorithmically generated author record based on publicly available information.

Abhinav Dey has a total of 556 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In Vitro Screening Assay for Activators of T-Cell Migration to Solid Tumors

    by Abhinav Dey, David J. Sharp

    Recently, chimeric antigen receptor (CAR) T-cell therapy has begun to be used for solid tumors such as glioblastoma multiforme. Pediatric malignant brain tumors patients develop extensive long-term morbidity of intensive multimodal curative treatment. CAR T-cells treatments could potentially create favorable outcomes and reduce the toxicity of current treatment. T-cell infiltration of solid tumors has been associated with good prognosis. A largely overlooked area of CAR T-cell therapy targeting solid tumors is enhancing the ability of CAR T-cells to migrate and infiltrate solid tumors. A potential reason could be lack of standard in vitro assays which can screen for genetic modifications that result in enhanced T-cell migration in CAR T-cell therapies. We report a novel coculture assay using 3D tumor spheroids cocultured with T-cells to analyze the effect of activating CAR T-cell interventions on cell migration by a simple imaging based readout. This assay can be applied to several different kinds of cancer cell lines in higher throughput as well as toward measuring the efficiency of currently available CAR T-cell therapies in untested solid tumors.


  • 3D-on-2D: A Physiologically Relevant and Gel-Free In Vitro Coculture Method to Assay Antimetastatic Agents

    by Abhinav Dey, Samuel Eisenberg, Rayna Birnbaum, David J. Sharp

    Metastasis of cancer cells leads to 90% of lethality among cancer patients. A crucial step in the hematogenous spread of metastatic cancer is the detachment of cells from the primary tumor followed by invasion through nearby blood vessels (Wong and Hynes. Cell Cycle 5(8):812–817, 2006). This is common to several solid tumors, including medulloblastoma (Van Ommeren et al. Brain Pathol 30:691–702, 2020). Because invasion is a crucial step in metastasis, the development of assays studying invasion are important for identifying antimetastatic drugs. There is always a need to develop better 3D in vitro models that not only mimic the complexity of in vivo architecture of solid tumors and their microenvironment, but are also simple to execute in medium to high throughput. We developed an in vitro coculture invasion assay that relies on the binary interaction between cancer cells and endothelial cells for research on tumor invasion and antimetastatic drug discovery. The goal of the current protocol is to use the simplicity of a two-dimensional endothelial cell culture to create a gel-free physiological substratum that can facilitate cancer cell invasion from a 3D cancer spheroid. This provides a simple and reproducible biomimetic 3D cell-based system for the analysis of invasion capacity in large populations of tumor spheroids. Using this assay, we can compare the effect of invasion inhibitors/activators on cancer spheroids. The results are analyzed by manual scoring of images for the presence or absence of sprouting from cancer spheroids. This enables simple and fast analysis of metastasis, which facilitates multiparameter examination.


  • Preclinical Research Strategy Development for RNAi-Based Therapies in Oncology Using Patient-Centered Information from Public Databases of Human Protein Atlas and R2Genomics Platform

    by Abhinav Dey, Isabelle Balachandran, Ava Solis, David J. Sharp

    Experimental anticancer agents have a history of failing in the late stages of clinical development, which has led to significantly increased losses to stakeholders during the drug development process. A bioinformatics-based approach to predict and derisk a drug development program can save time, effort, and expenses resulting from failure of experimental anticancer agents in preclinical/early clinical stages. We present a two-step in silico ensemble method, involving the comparison of localized gene expression from surrounding tissue with tumor tissue, and subsequent correlation with patient survival data, which can help predict safety and efficacy for siRNA-based drug delivery to internal cancer tissues. This is achieved by reducing the possible off-target effects due to reduced or minimal expression of the drug target in surrounding tissue, and increasing survival probability for patients whose cancers can be controlled/eliminated by siRNA-mediated inhibition of drug target. This kind of approach can be useful for more efficient drug development efforts in oncology through reduction of investment in expensive experimentation during the discovery and preclinical phases; and ultimately support the intended clinical trial design.


  • Open Access

    A Novel Therapeutic Approach to Corneal Alkaline Burn Model by Targeting Fidgetin-Like 2, a Microtubule Regulator

    by Jessie Wang, Abhinav Dey, Adam H. Kramer, Yuan Miao, Juan Liu, Lisa Baker, Joel M. Friedman, Parimala Nacharaju, Roy S. Chuck, Cheng Zhang, et al.

    Purpose: The purpose of this study was to determine the efficacy of nanoparticle-encapsulated Fidgetin-like 2 (FL2) siRNA (FL2-NPsi), a novel therapeutic agent targeting the FL2 gene, for the treatment of corneal alkaline chemical injury. Methods: Eighty 12-week-old, male Sprague-Dawley rats were divided evenly into 8 treatment groups: prednisolone, empty nanoparticles, control-NPsi (1 µM, 10 µM, and 20 µM) and FL2-NPsi (1 µM, 10 µM, and 20 µM). An alkaline burn was induced onto the cornea of each rat, which was then treated for 14 days according to group assignment. Clinical, histopathologic, and immunohistochemical analyses were conducted to assess for wound healing. FL2-NPsi-mediated knockdown of FL2 was confirmed by in vitro quantitative polymerase chain reaction (qPCR). Toxicity assays were performed to assess for apoptosis (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling [TUNEL] assay) and nerve damage (whole mount immunochemical staining). Statistical analyses were performed using Student's t-test and ANOVA. Results: Compared with controls, FL2-NPsi-treated groups demonstrated enhanced corneal wound healing, with the 10 and 20 µM FL2-NPsi-treated groups demonstrating maximum rates of corneal re-epithelialization as assessed by ImageJ software, enhanced corneal transparency, and improved stromal organization on histology. Immunohistochemical analysis of vascular endothelial cells, macrophages, and neutrophils did not show significant differences between treatment groups. FL2-NPsi was not found to be toxic to nerves or induce apoptosis (p = 0.917). Conclusions: Dose-response studies found both 10 and 20 µM FL2-NPsi to be efficacious in this rat model. FL2-NPsi may offer a novel treatment for corneal alkaline chemical injuries. Translational Relevance: Basic cell biology findings about the microtubule cytoskeleton were used to design a therapeutic to enhance corneal cell migration, highlighting the promise of targeting microtubules to regulate corneal wound healing.


  • Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma

    by Jinhwan Kim, Abhinav Dey, Anshu Malhotra, Jingbo Liu, Song Ih Ahn, Yoshitaka J. Sei, Anna M. Kenney, Tobey J. MacDonald, YongTae Kim

    Significance: This study shows that an engineered biomimetic nanoparticle decorated with a targeting ligand and loaded with a sonic hedgehog inhibitor maintains its stability in the circulation, crosses the blood–brain barrier (BBB), and delivers drug molecules to the cancer stem-like cell population in sonic hedgehog subtype of medulloblastoma. Leveraging the natural capabilities of high-density lipoprotein, our nanoparticle enables the facilitated and targeted cellular uptake of drugs and receptor-mediated intracellular cholesterol depletion in medulloblastoma cells. Our successful in vivo validation of the nanocarrier performance suggests a new viable strategy by which to deliver other drugs that are reportedly unable to cross the BBB, have low bioavailability, and/or off-target effects for the treatment of brain tumors, including medulloblastoma.


  • Open Access

    The kinesin-8 member Kif19 alters microtubule dynamics, suppresses cell adhesion, and promotes cancer cell invasion

    by Samuel C. Eisenberg, Abhinav Dey, Rayna Birnbaum, David J. Sharp

    Metastasis is one of the deadliest aspects of cancer. Initial Metastatic spread is dependent on the detachment and dissemination of cells from a parent tumor, and invasion into the surrounding tissue. In this study, we characterize the kinesin-8 member Kif19 as a promoter of cancer cell invasion that suppresses cell-cell adherens junctions and cell-matrix focal adhesions. Initial analysis of publicly available cancer patient data sets demonstrated that Kif19 expression correlates with worse overall survival probability in several cancers and that Kif19 expression is increased in metastases of colorectal and breast carcinoma compared to the primary tumor. Depletion of Kif19 from two human cancer cell lines (DMS53 and MDA-MB-231) did not alter viability, but decreased the cells’ ability to invade a Matrigel matrix by half and impaired the invasion of spheroids into a primary cell monolayer. Ectopically expressed Kif19 localized to, and partially depolymerized, microtubules in the cell periphery. However, Kif19 depletion increased microtubule dynamicity and sensitivity to pharmacological depolymerization without altering total microtubule polymer levels. These data indicate that Kif19 can both depolymerize and stabilize microtubules. Given this activity, we then studied Kif19’s effect on focal adhesions and adherens junctions, which are both regulated by microtubule dynamics. Kif19 knockdown increased the proportion of cell surface area covered by Vinculin focal adhesions. Further, Kif19 depletion increased whole cell E-cadherin expression and the accumulation of E-cadherin at cell-cell adherens junctions. Conversely, ectopic overexpression of full-length Kif19 led to proportionally smaller focal adhesions and impaired E-cadherin accumulation at cell-cell junctions. Our current hypothesis is that aberrant Kif19 expression in cancer alters focal adhesion dynamics and suppresses E-cadherin expression, which enhance cell invasiveness. Further, we propose that these changes in cell adhesion are due to modification of peripheral microtubule dynamics by Kif19, potentially through disruption of local rho GTPase activity.